Because of its ability to not only directly modulate lipid metabolism in the liver but also to improve whole-body metabolic homeostasis, the PPARα–FGF21 axis has emerged as a promising target for the treatment of NAFLD and NASH. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.